The global biomarkers market was valued at USD 38.41 billion in 2018 and is expected to soar to USD 190.81 billion by 2032, registering a robust CAGR of 12.1% over the forecast period. In 2018, North America led the biomarkers market, accounting for a dominant market share of 38.53%.
The biomarkers market is gaining momentum due to its vital role in disease diagnosis, prognosis, and therapeutic monitoring across a wide range of medical conditions, including cancer, cardiovascular diseases, neurological disorders, and infectious diseases. Biomarkers enable early detection and personalized treatment, thereby improving clinical outcomes and reducing healthcare costs. The growing focus on precision medicine, coupled with advancements in genomics, proteomics, and bioinformatics, is driving innovation in the field. Increased investments in biomarker research, rising demand for non-invasive diagnostic techniques, and the growing adoption of companion diagnostics in targeted therapies are further fueling market growth. As healthcare systems worldwide shift towards more predictive and preventive approaches, the biomarkers market is expected to witness sustained expansion in the years ahead.
Continue reading for more details:
**https://www.fortunebusinessinsights.com/biomarkers-market-102173**
Biomarkers Market: Market Segmentation
The biomarkers market is segmented by type into safety biomarkers, efficacy biomarkers, and validation biomarkers.
Based on application, the market includes diagnostics, drug discovery & development, personalized medicine, and disease risk assessment.
The market is also segmented by disease area, covering oncology, cardiovascular disorders, neurological diseases, and infectious diseases.
By end-user, the biomarkers market includes pharmaceutical & biotechnology companies, hospitals & clinics, diagnostic laboratories, and research institutes.
List Of Key Companies Covered: